Gene Expression That Predicts Radiation Exposure in Humans

NCT ID: NCT03123133

Last Updated: 2021-04-21

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 151 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-04-06
• Study Completion Date: 2020-07-14

Brief Summary

To verify and validate a biodosimetry test for determining absorbed ionizing radiation dose by analyzing gene expression signatures of blood samples collected from patients treated with Total Body Irradiation (TBI).

Detailed Description

In order validate the performance of DxTerity's Radiation Biodosimetry Test (RBT) system, several clinical centers will provide controlled, de-identified blood samples and associated clinical information to DxTerity Diagnostics (DxTerity). Variations in dose and frequency of delivery in TBI protocols are expected between the clinical centers and this has been accounted for in the study design. Samples from up to 200 participants will be collected via this protocol. Blood samples for this study will be collected from radiation therapy patients receiving TBI as part of a therapeutic regimen from the site.

Blood samples (up to 4 mL per time point) may be obtained at the time of routine blood collection; participation in this biomarker study will not affect any aspect of patient treatment. Study samples will be obtained prior to, during, and post-radiation treatment regimen. Associated clinical information will be collected from the subject's medical record, as well.

Conditions

Total Body Irradiation

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

1. Male and female patients age 2 or older.

2. Weigh at least 13kg (30lbs), and in the opinion of the investigator, are healthy enough to participate in study activities.

3. Evidence of a personally signed and dated informed consent/assent document indicating that the subject or a legally acceptable representative (parent(s)/legal guardian) has been informed of all pertinent aspects of the study.

4. Diseases treated with HSCT, including malignant and nonmalignant diseases.

5. Planned fractionated total body irradiation (TBI) as part of clinical care with a cumulative dose ≥6 Gy or a single dose between 1.5 and 3.0 Gy.

Exclusion Criteria

1. Subjects who have received chemotherapy within 21 days prior to TBI.

2. Concurrent chemotherapy with Fludarabine or an investigational product

3. Cytokine inhibitor or cytokine-inducer therapy within 30 days prior to and during the irradiation regimen

4. Subjects who have received GCSF within 30 days prior to TBI

5. Participants, who in the opinion of the investigator, may not be able to comply with the requirements of the study.

• Minimum Eligible Age: 2 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biomedical Advanced Research and Development Authority

FED

Sponsor Role: collaborator

DxTerity Diagnostics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aviva Jacobs, PhD

Role: STUDY_DIRECTOR

Director, Product Developement

Locations

City of Hope

Duarte, California, United States

University of California, Los Angeles, Radiation Oncology

Los Angeles, California, United States

Fred Hutch Cancer Research Center

Seattle, Washington, United States

Countries

United States

Other Identifiers

DXT-RBT-AB01

Identifier Type: -

Identifier Source: org_study_id